Hofon Capital
华方资本
Hofon Capital (华方资本) is a Chinese venture capital firm that appears as a co-investor alongside more established funds, though elsewhere's corpus contains limited direct information about the firm itself. Per 峰瑞资本 (FreeS Capital) reports from 2021 and 2025, Hofon Capital participated in follow-on rounds for Chemical.AI's ~$15 million Series A+ and 穹顶医疗's tens-of-millions RMB Series A, in both cases investing alongside Sequoia China, 源码资本 (Source Code Capital), and others . A 2024 高榕创投 (Gaorong Ventures) article also lists Hofon Capital as a follow-on investor in 篆芯半导体's ~200 million RMB Series A2 round for AI networking chips . The pattern suggests Hofon operates as a co-investor in hard-tech and healthcare deals, but elsewhere has not published a standalone profile of its founding team, vintage, or assets under management.
AI-generated — may contain errors, please verify.
Coverage
7 Interdisciplinary Companies Close New Funding Rounds | FreeS Family Funding News Vol.22
Looking forward to working alongside more outstanding founders.
High-end networking chip company **Zhuanxin** has completed its Series A2 funding round, targeting the AI computing network market.
Meeting the high-bandwidth networking demands of AI computing clusters.
Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
